Oculis (NASDAQ:OCS) Sets New 52-Week Low – What’s Next?

Oculis Holding AG (NASDAQ:OCS)’s share price reached a new 52-week low during trading on Friday. The company traded as low as $8.30 and last traded at $8.34, with a volume of 161,880 shares. The stock had previously closed at $8.66.

Analyst Ratings Changes

A number of research firms have recently weighed in on OCS. Wall Street Zen upgraded Oculis from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. JPMorgan Chase & Co. decreased their price objective on shares of Oculis from $23.00 to $20.00 and set an “overweight” rating on the stock in a research note on Friday, August 14th. HC Wainwright boosted their target price on Oculis from $26.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, September 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a research report on Friday, July 17th. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $39.44.

Oculis Stock Down 3.7%

The firm has a market capitalization of $483.55 million, a price-to-earnings ratio of -4.79 and a beta of 0.62. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.35 and a quick ratio of 8.35. The stock has a fifty day moving average of $11.23 and a two-hundred day moving average of $17.08.

Oculis (NASDAQ:OCS) last announced its earnings results on Tuesday, June 30th. The company reported ($0.20) EPS for the quarter. Oculis had a negative return on equity of 42.61% and a negative net margin of 6,777.18%. The company had revenue of $0.38 million for the quarter. Sell-side analysts anticipate that Oculis Holding AG will post -2.01 earnings per share for the current year.

Institutional Trading of Oculis

Institutional investors have recently added to or reduced their stakes in the stock. Koshinski Asset Management Inc. acquired a new position in shares of Oculis in the 1st quarter worth approximately $238,000. Himension Capital Singapore PTE. LTD. bought a new position in shares of Oculis in the 1st quarter worth about $503,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Oculis during the 1st quarter valued at about $776,000. Squarepoint Ops LLC grew its stake in Oculis by 326.4% during the second quarter. Squarepoint Ops LLC now owns 61,605 shares of the company’s stock worth $854,000 after purchasing an additional 47,158 shares during the period. Finally, Bank of America Corp DE lifted its stake in Oculis by 9.1% in the first quarter. Bank of America Corp DE now owns 69,764 shares of the company’s stock valued at $1,855,000 after buying an additional 5,813 shares during the period. 22.30% of the stock is currently owned by institutional investors.

Oculis Company Profile

Oculis (NASDAQ: OCS) is a biopharmaceutical company focused on developing and commercializing innovative treatments for eye diseases. The company aims to address significant unmet needs in ophthalmology through therapies designed for topical, noninvasive administration and other targeted delivery approaches.

Oculis’ pipeline has included OCS-01, a topical dexamethasone formulation being developed for retinal diseases such as diabetic macular edema, and licaminlimab (OCS-02), an ophthalmic anti-TNF biologic being investigated for conditions including dry eye disease.